Business Context and Reporting Period
This Form 8-K is a current report filed by Aileron Therapeutics, Inc. (not Rein Therapeutics, Inc.) on May 15, 2024. The report discloses a material change in executive leadership regarding the Company's financial officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Charles Garner departed the Company on May 15, 2024, vacating the roles of Principal Financial Officer and Principal Accounting Officer.
- Appointment: The Board appointed Timothy M. Cunningham as Interim Chief Financial Officer, effective May 16, 2024.
- Compensation Structure: Mr. Cunningham will serve via a consulting agreement with Danforth Advisors, LLC. The Company will pay an agreed-upon hourly rate and reimburse expenses.
- Termination Terms: The agreement allows termination with cause upon 30 days' written notice, or without cause upon 60 days' written notice.
Management Commentary and Risks
Management highlighted Mr. Cunningham's extensive experience in the life sciences sector, including roles as CFO for Bionomics Limited, acting CFO for Peak Bio, Inc. and SAB Biotherapeutics, Inc., and CFO at Organogenesis. He holds an MBA from Boston University, a BS in Accounting from Boston College, and is a CPA in Florida. No specific risks or contingencies related to financial performance were disclosed in this filing.
Investor Verification Checklist
- Verify the effective date of the interim CFO appointment (May 16, 2024).
- Confirm the hourly rate and expense reimbursement terms in the consulting agreement with Danforth Advisors, LLC.
- Review the Company's subsequent filings for the appointment of a permanent Chief Financial Officer.
- Check for any undisclosed liabilities or financial impacts associated with Mr. Garner's departure.